Diabetes
Roche Continues to Reap Rewards of Carmot Buyout with Strong Early GLP-1 Data
Roche, Carmot Therapeutics, GLP-1/GIP receptor agonist, CT-388, obesity treatment, weight loss, diabetes, pharmaceutical industry
CordenPharma Invests €900M in Peptide Manufacturing Expansion to Meet Rising Demand for GLP-1 Medications
CordenPharma, GLP-1, peptide manufacturing, expansion, investment, diabetes, obesity, pharmaceutical industry
FDA Rejects Novo Nordisk’s Once-Weekly Insulin Icodec for Diabetes Treatment
FDA, Novo Nordisk, Icodec, Weekly Insulin, Diabetes Treatment, Type 1 Diabetes, Type 2 Diabetes, Complete Response Letter
GLP-1s May Cut Risk of 10 Obesity-Related Cancers in Diabetes Patients: Study
GLP-1, Obesity-Related Cancers, Diabetes Patients, Cancer Prevention, Weight Loss
EU Calls for Cooperation and Increased Manufacturing to Overcome GLP-1 Shortage
GLP-1 receptor agonists, EU, shortages, diabetes, weight management, manufacturing, cooperation, regulatory actions
Teladoc Research Highlights the Impact of AI-Powered ‘Nudges’ on Diabetes Management
Teladoc Health, AI-powered nudges, diabetes management, personalized health, predictive modeling, chronic condition management, virtual care
Eli Lilly’s Zepbound Shows Promise in Treating Sleep Apnea, Seeks FDA Approval
Zepbound, Eli Lilly, sleep apnea, FDA approval, Novo Nordisk, Wegovy, weight loss, diabetes, pharmaceuticals
Fractyl Highlights GLP-1 Gene Therapy Potential, Delays Clinical Trials to 2025
Fractyl, GLP-1 gene therapy, clinical trials, diabetes, ADA24
Vertex Announces Positive Results for VX-880 in Type 1 Diabetes Treatment
Vertex Pharmaceuticals, VX-880, Type 1 Diabetes, Stem Cell Therapy, Insulin Independence, Severe Hypoglycemic Events
Syntis Bio Launches Revolutionary Oral Therapy to Mimic Weight-Loss Surgery
Syntis Bio, weight-loss surgery, oral therapy, obesity, diabetes, rare diseases, SYNT-101, gastric bypass surgery, small intestine, metabolic control, digestion, drug absorption.